Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Hua

Showing results (71-80 of 101) with videos related to

Pageof 11
Sort By:
Journal of the American College of Cardiology|July 13, 2010
Cardiovascular events during differing hypertension therapies in patients with diabetesMichael A Weber, George L Bakris, Kenneth Jamerson, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|November 14, 2016
Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure: insights from the RELAX-AHF studySven Meyer, John R Teerlink, Marco Metra, et al.
Platelets|July 10, 2003
Effects of the glycoprotein IIb/IIIa antagonist Roxifiban on P-selectin expression, fibrinogen binding, and microaggregate formation in a phase I dose-finding study: no evidence for platelet activation during treatment with a glycoprotein IIb/IIIa antagonistDietmar Seiffert, Beth E Thomas, Jodi D Bradley, et al.
Oncogene|June 12, 2013
Parathyroid hormone-related protein inhibits DKK1 expression through c-Jun-mediated inhibition of β-catenin activation of the DKK1 promoter in prostate cancerH Zhang, C Yu, J Dai, et al.
European Journal of Heart Failure|October 8, 2014
Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome--an analysis from RELAX-AHFAdriaan A Voors, Beth A Davison, John R Teerlink, et al.
Journal of Cardiac Failure|November 10, 2016
Evaluating the Efficacy, Safety, and Tolerability of Serelaxin When Added to Standard Therapy in Asian Patients With Acute Heart Failure: Design and Rationale of RELAX-AHF-ASIA TrialNaoki Sato, Carolyn S P Lam, John R Teerlink, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 30, 2002
Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysisJames W Hainer, Donald J Sherrard, Suzanne K Swan, et al.
Blood Pressure|August 12, 2011
Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH StudySverre E Kjeldsen, Kenneth A Jamerson, George L Bakris, et al.
Blood Pressure|June 24, 2008
Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH studySverre E Kjeldsen, Kenneth A Jamerson, George L Bakris, et al.
JAMA|March 13, 2013
Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trialMihai Gheorghiade, Michael Böhm, Stephen J Greene, et al.
Pageof 11

Showing results (71-80 of 101) with videos related to

Sort By:
Pageof 11
Journal of the American College of Cardiology|July 13, 2010
Cardiovascular events during differing hypertension therapies in patients with diabetesMichael A Weber, George L Bakris, Kenneth Jamerson, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|November 14, 2016
Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure: insights from the RELAX-AHF studySven Meyer, John R Teerlink, Marco Metra, et al.
Platelets|July 10, 2003
Effects of the glycoprotein IIb/IIIa antagonist Roxifiban on P-selectin expression, fibrinogen binding, and microaggregate formation in a phase I dose-finding study: no evidence for platelet activation during treatment with a glycoprotein IIb/IIIa antagonistDietmar Seiffert, Beth E Thomas, Jodi D Bradley, et al.
Oncogene|June 12, 2013
Parathyroid hormone-related protein inhibits DKK1 expression through c-Jun-mediated inhibition of β-catenin activation of the DKK1 promoter in prostate cancerH Zhang, C Yu, J Dai, et al.
European Journal of Heart Failure|October 8, 2014
Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome--an analysis from RELAX-AHFAdriaan A Voors, Beth A Davison, John R Teerlink, et al.
Journal of Cardiac Failure|November 10, 2016
Evaluating the Efficacy, Safety, and Tolerability of Serelaxin When Added to Standard Therapy in Asian Patients With Acute Heart Failure: Design and Rationale of RELAX-AHF-ASIA TrialNaoki Sato, Carolyn S P Lam, John R Teerlink, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 30, 2002
Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysisJames W Hainer, Donald J Sherrard, Suzanne K Swan, et al.
Blood Pressure|August 12, 2011
Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH StudySverre E Kjeldsen, Kenneth A Jamerson, George L Bakris, et al.
Blood Pressure|June 24, 2008
Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH studySverre E Kjeldsen, Kenneth A Jamerson, George L Bakris, et al.
JAMA|March 13, 2013
Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trialMihai Gheorghiade, Michael Böhm, Stephen J Greene, et al.
Pageof 11